3 Dividend Stocks to Buy and Hold for 10 Years

The article identifies Pfizer, Abbott Laboratories and Medtronic as long-term healthcare income investments, highlighting Pfizer's 6.2% forward dividend yield, Abbott's 50-plus-year dividend-increase record, and Medtronic's 49-year streak. Abbott reported Q2 comparable sales growth of 4.8% to $12.6 billion and adjusted EPS growth of 4% to $1.31, supported by medical devices, while its $21 billion Exact Sciences acquisition broadens its cancer-diagnostics opportunity. Medtronic posted fiscal Q1 2027 revenue growth of 13.7% to $9.8 billion, with cardiac-ablation revenue up 88%, and expects its diabetes-care separation plus Hugo robotic-surgery expansion to support longer-term growth; Pfizer is positioned for a potential recovery through pipeline assets despite COVID-product weakness and upcoming patent expirations.

Analysis

The actionable signal is not the dividend framing but a potential quality re-rating within large-cap medtech. ABT has the cleanest earnings resilience if procedure volumes remain healthy: Libre’s installed-base economics and structural-heart mix can offset weaker consumer-sensitive nutrition, while oncology diagnostics is a longer-duration call option rather than a near-term earnings driver. The principal risk is that the Exact Sciences transaction creates dilution and integration drag before any revenue synergy is measurable; EXAS holders are likely the more direct near-term beneficiary if a definitive transaction remains executable.

MDT offers a more distinct 6-18 month catalyst path. Separating diabetes could improve the remaining company’s margin profile and make its hospital-facing portfolio easier to value against higher-quality pure-play medtech peers, while ablation and robotic-surgery adoption create operating leverage if utilization persists. The market may be underestimating execution risk: a slower-than-expected diabetes separation, incremental Hugo capital-placement costs, or hospital budget pressure would prevent the anticipated multiple expansion.

PFE remains primarily a pipeline and capital-allocation debate, not a yield trade. A high payout does not itself validate dividend safety while post-COVID cash generation, debt reduction, and looming loss-of-exclusivity require competing uses of capital. Weight-loss optionality is unlikely to support the equity over the next 1-3 months absent differentiated clinical data; the relevant bar is durable efficacy, tolerability and dosing convenience versus entrenched incretin competitors, not merely pipeline advancement.

Key Decisions for Investors

• Initiate a 6-12 month long MDT / short PFE pair, sized beta-neutral. MDT has identifiable separation and procedure-growth catalysts; PFE needs clinical or commercial proof to escape an ex-growth valuation. Reassess if MDT’s organic growth decelerates below management’s medium-term target or if separation timing slips materially.
• Accumulate ABT on any transaction-related weakness rather than chase broad healthcare strength; target a 9-18 month hold. The thesis requires medical-device growth to remain mid-single-digit or better and acquisition financing not to materially impair EPS accretion expectations. Reduce if Libre growth slows sharply or nutrition weakness spreads beyond an isolated segment issue.
• Treat EXAS as an event-driven watch item, not a standalone post-deal long. Confirm consideration structure, antitrust timetable, termination protections and pro forma leverage before positioning; a cash-heavy structure can cap upside while regulatory delay creates meaningful spread risk.
• Avoid adding PFE solely for income over the next 3-6 months. Upgrade only following independently validated evidence that new-product growth and cost actions cover the patent-cliff trajectory while net-debt reduction and dividend funding remain compatible.